Type
2 diabetes affects more than 530 million adults worldwide,
and the number is projected to climb sharply by 2050.
For most of the last century, the medical consensus
treated it as a progressive, lifelong condition. Patients
were taught to monitor blood sugar, take daily medication,
and prepare for complications. Yet mounting clinical
evidence shows that Type 2 diabetes is often preventable
and, in many cases, reversible through changes in diet,
weight, and activity.
This gap between what is biologically possible and what
is economically common raises an uncomfortable question:
Has a system emerged that is structurally better at
managing diabetes than ending it? Critics use the phrase
“diabetic industrial complex” to describe
it — not a formal conspiracy, but a web of interlocking
industries and incentives that generate recurring revenue
from chronic care.
The phrase borrows from Dwight Eisenhower’s “military-industrial
complex.” In that context, defense contractors,
government agencies, and legislators became mutually
dependent, making perpetual military readiness profitable.
Applied to diabetes, the argument is that pharmaceutical
firms, device manufacturers, food companies, healthcare
providers, insurers, and even parts of medical education
now benefit from a large, stable pool of patients who
require lifelong products and services. When people
first hear the phrase “diabetic industrial complex,”
they picture a smoke-filled room of executives plotting
to keep patients sick. That image misses the point.
The critique is not about moral failure at the individual
level. It’s about structural incentives. When
billions of dollars in recurring revenue depend on a
chronic condition, institutions — companies, hospitals,
insurers, regulators, even nonprofits — adapt
to sustain that revenue. Over time, the system becomes
extraordinarily good at managing diabetes, and surprisingly
slow at making it disappear.
This
is not unique to diabetes. Any market built around chronic
disease faces the same tension: prevention and remission
shrink the customer base, while management expands it.
What makes diabetes notable is the scale. More than
530 million adults worldwide live with the condition,
90–95% of them with Type 2. Global spending on
diabetes care exceeds $1 trillion annually. At that
size, small biases in incentives compound into a healthcare
ecosystem with its own momentum.
In
economics, an “incentive structure” is simply
the set of rewards and penalties that shape decisions.
No one has to intend harm for the system to produce
suboptimal public health. Three examples illustrate
this.
Pharmaceutical
development. Drug companies are rational actors. Developing
a once-daily pill that lowers blood sugar is a clear
business case: large market, lifelong use, insurance
coverage. Developing a one-time intervention that induces
remission is scientifically harder and commercially
riskier. Even if it worked, the addressable market would
contract after each cured patient. So capital flows
toward management, not resolution. That is not malice;
it is math.
Clinical
practice. Most health systems still reimburse fee-for-service.
A 15-minute visit to adjust insulin, an A1C lab draw,
a prescription refill, a referral to nephrology —
each generates a billing code. A 60-minute counseling
session on nutrition, or a six-month program that gets
a patient off medication, often does not. Physicians
respond to what the system measures and pays for. Again,
no physician wakes up planning to perpetuate diabetes.
They work within the rules they’re given.Food
and marketing. Ultra-processed foods high in refined
carbs and added sugars are shelf-stable, palatable,
and cheap to produce. They drive repeat purchase and
brand loyalty. Companies that sell them also fund research,
sponsor dietitian associations, and market “diabetes-friendly”
product lines. The result is a food environment that
promotes insulin resistance on one shelf and sells glucose
meters on another. Coordinated intent isn’t required;
parallel incentives are enough.
Because
each player optimized locally, the whole system optimized
for permanence. Here is what that looks like in practice.
Drug
manufacturers generate revenue through monthly refills
of insulin, GLP-1s, and SGLT2s, which control glucose
but often leave underlying insulin resistance unaddressed;
device makers profit from recurring sales of strips,
sensors, and pumps that improve monitoring while creating
dependence on supplies; providers and hospitals earn
from visits, labs, and procedures for complications,
treating downstream damage like dialysis, amputations,
and retinopathy; insurers and PBMs collect premiums
and rebates tied to high list-price drugs, favoring
therapies with financial spreads over the lowest-cost
outcomes; the food industry drives volume sales of refined
carbs and snacks that increase population-level insulin
resistance; and medical education, shaped by industry
grants and limited nutrition training, generates revenue
while producing clinicians who are taught to prescribe
before they counsel.
The output of this ecosystem is impressive: a person
diagnosed with Type 1 diabetes in 1920 had months to
live. Today, they can expect a near-normal lifespan.
A person with Type 2 can access drugs that cut heart-attack
risk and devices that warn of lows in real time. We
got very good at keeping people alive with diabetes.
What
we did not get good at was creating fewer people with
diabetes.
Management
means controlling biomarkers. For diabetes, the key
metric has been hemoglobin A1C. If drugs and devices
push A1C under 7%, the case is considered a success,
even if the patient’s insulin levels remain high,
weight continues to climb, and medication doses escalate
yearly. The disease is “controlled,” not
gone.
Reversal,
or remission, means restoring normal glucose without
medication. Trials like DiRECT in the UK and Virta Health’s
U.S. studies show this is possible for many people with
Type 2, typically through significant weight loss and
carbohydrate reduction. Remission is not a cure —
beta-cell function may still be impaired — but
it changes the economic equation. A patient in remission
buys fewer drugs, fewer strips, and needs fewer specialist
visits.
From
a public-health perspective, remission is a win. From
a recurring-revenue perspective, it is a leak in the
bucket. The system, therefore, did not evolve to prioritize
it. Medical guidelines only formally recognized remission
as a therapeutic goal in 2021. Insurance coverage for
remission programs remains spotty in 2026. That lag
is the footprint of misaligned incentives.
Calling
the complex a critique of incentives, not individuals,
matters for two reasons.
First,
it avoids the trap of villain narratives. Physicians
are not withholding cures. Most would celebrate a world
without Type 2 diabetes. Scientists at drug companies
are not suppressing solutions; they work on the projects
that get funded. Food scientists are not trying to cause
disease; they optimize for taste, cost, and shelf life
because their bonuses depend on it. If we fire all the
people and keep the incentives, the system reproduces
itself with new faces.
Second,
it points to the actual leverage points. You don’t
fix incentives with outrage. You fix them by changing
what gets paid for, measured, and rewarded. When Medicare
capped insulin at $35 a month, three manufacturers dropped
prices across the board within weeks. When employers
started paying for outcomes instead of visits, remission
clinics suddenly became viable businesses. Incentives
are policy choices, and policy can change.
Ironically,
the same profit motive that built the complex is now
creating cracks in it. Continuous glucose monitors,
once a niche device for insulin users, are now marketed
for “metabolic health” to millions without
diabetes. That expands the device market but also gives
users real-time feedback on food, nudging behavior change
that reduces future drug use.
GLP-1
drugs like semaglutide and tirzepatide were developed
for diabetes, but their weight-loss effect is so strong
that obesity became the larger market. A patient who
loses 15% of body weight may never progress from prediabetes
to diabetes at all. The drug that treats the condition
is also preventing new cases — a rare alignment
of profit and public health.
Startups
now contract with insurers on a “pay for remission”
basis. If A1C goes down and meds get deprescribed, the
startup gets paid. If not, it doesn’t. That inverts
the old model: revenue now depends on making diabetes
disappear, at least in that patient.
So
the complex is not static. It is an adaptive system.
When the money moves, the system moves.
The
diabetic industrial complex is a description of emergent
behavior, not a criminal indictment. It explains why
a society that can land rovers on Mars still struggles
to reduce soda consumption in schools. It explains why
we have artificial pancreas systems but not widespread
remission clinics.
We
became extraordinarily good at keeping people alive
with diabetes because we built an economy that rewards
it. We will become good at making diabetes disappear
when we build an economy that rewards that instead.
The
critique, then, is also an invitation. Incentives are
human-made. If the current ones gave us a trillion-dollar
chronic-disease industry, different ones could give
us a population where Type 2 diabetes is rare, remission
is common, and “management” is the exception,
not the rule.
That
future won’t be achieved by blaming individuals
inside the system. It will be achieved by redesigning
the system so that the right thing for a patient is
also the rational thing for every institution they touch.
